Echo Therapeutics, Inc. (ECTE.OB) Files for FDA Clearance

QualityStocks would like to highlight Echo Therapeutics (OTCBB: ECTE). Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes, and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

In the company’s news yesterday,

Echo reported submission of a 510(k) premarket notification to the FDA today for its Prelude System and 4% lidocaine cream (anticipated market clearance is 90 days).

Having developed the Symphony, a needle-free, non-invasive and wireless system, around the Prelude system, ECTE believes the technology offers unprecedented quality of life for diabetics, especially for patients in critical care or ambulatory environments.

President, Chairman and CEO of ECTE, Patrick T. Mooney, M.D., called this news a major milestone in the Company’s drive to create novel applications for its proprietary technology.

This announcement follows fast on the heels of a clinical study in August of this year, which analyzed the use of Prelude to prep the skin before applying the OTC 4% lidocaine cream as a fast-acting local dermal anesthesia.

Dr. Mooney explained that the use of Prelude to effectively enhance topical lidocaine use represents a huge near-term revenue stream for the Company. He also hailed partner Ferndale Pharma Group, Inc., showing clear excitement over the pending FDA clearance of the product and subsequent generation of royalties from sales.

Ferndale was granted a North America and UK license to use Prelude as a skin prep for topical analgesics, anaethetic cream or local dermal anesthesia prior to needle insertion or IV via a May 2009 agreement with ECTE.

The Company is slated to receive a $750k milestone payment, in addition to a double-digit royalty on product sales, once FDA clearance is granted.

It is clear that the Prelude System has a wide range of potential applications throughout the therapeutics market and ECTE is confident that today’s submission and the eventual approval of the system will lead to continued prosperity for the Company.

The Prelude System uses a patented skin permeating feedback control technology developed by ECTE, which, in conjunction with the wireless hand-held device, enables efficient permeation of the tough outer skin layer. The Prelude preps a small area of skin for the Symphony’s non-invasive biosensor/transceiver or for the transdermal application of various drugs.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.